Reuters logo
BRIEF-Sarepta Therapeutics reports positive results in study
2017年9月6日 / 上午11点26分 / 15 天前

BRIEF-Sarepta Therapeutics reports positive results in study

Sept 6 (Reuters) - Sarepta Therapeutics Inc

* Sarepta Therapeutics announces positive results in its study evaluating gene expression, dystrophin production, and dystrophin localization in patients with duchenne muscular dystrophy (DMD) amenable to skipping exon 53 treated with golodirsen (SRP-4053)

* Sarepta Therapeutics Inc - ‍study achieved statistical significance on all primary and secondary biological endpoints​

* Sarepta Therapeutics Inc - ‍study also showed a statistically significant increase in dystrophin immunofluorescence as measured by immunohistochemistry​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below